Peak Bio (PKBO) is anticipated to make its market debut Wednesday within the wake of the closing of its merger with SPAC Ignyte Acquisition Corp. (NASDAQ:IGNY).
The merger was authorised by Ignyte shareholders on Oct. 25. Shares of the mixed firm had been slated to start buying and selling on or about Nov. 2 on Nasdaq below the image PKBO.
Peak Bio has been engaged on therapies to deal with most cancers and inflammatory issues. The corporate’s lead product, PHP-303, is awaiting Section 2 testing for the remedy of the uncommon orphan genetic illness Alpha1 anti-trypsin deficiency dysfunction, or AATD.
The businesses introduced plans to merge in April via a deal that estimated the fairness worth of the mixed firm at round $278M.